FDA Inspection 1217646 — Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Liaoyuan Pharmaceutical Co., Ltd. on August 25, 2023 in Taizhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 25, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)